共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
Schiaffino MC Bellini C Costabello L Caruso U Jakobs C Salomons GS Bonioli E 《Neurogenetics》2005,6(3):165-168
Creatine transporter deficiency is an X-linked disorder characterized by mental retardation and language delay. The authors
report a patient affected by creatine transport deficiency caused by a novel mutation in the SLC6A8 gene. Impairment in social interaction represents a consistent clinical finding in the few cases described to date and may
be a diagnostic clue for creatine transporter deficiency in males affected by mental retardation, seizures, and language impairment. 相似文献
3.
Congenital creatine transporter deficiency 总被引:7,自引:0,他引:7
deGrauw TJ Salomons GS Cecil KM Chuck G Newmeyer A Schapiro MB Jakobs C 《Neuropediatrics》2002,33(5):232-238
BACKGROUND: Two inborn errors of metabolism of creatine synthesis as well as the X-linked creatine transporter (SLC6A8) deficiency have been recognized. This report describes the features of five identified male patients and their female relatives who are carriers of the X-linked creatine transporter deficiency syndrome. METHODS: Proton MR spectroscopy was used to recognize creatine deficiency in the patients. Molecular analysis of the SLC6A8 gene was performed, confirming the diagnosis of homozygous males and heterozygous females. RESULTS: We describe four families from a metropolitan area in the U. S. with X-linked creatine transporter deficiency. All affected males present with developmental delay and severe developmental language impairment. Proton MR spectroscopy shows significantly depressed to essentially absent creatine and phosphocreatine in the male patients. Nonsense mutations and amino acid deletions were found in the SLC6A8 gene in the affected families. CONCLUSION: Creatine transporter deficiency may be a more common X-linked genetic disorder than originally presumed. The affected males exhibit mental retardation with severe expressive language impairment. 相似文献
4.
Junpei Tanigawa Shin Nabatame Koji Tominaga Yoko Nishimura Yoshihiro Maegaki Taroh Kinosita Yoshiko Murakami Keiichi Ozono 《Brain & development》2021,43(6):680-687
ObjectiveWe aimed to assess the efficacy and safety of high-dose pyridoxine treatment for seizures and its effects on development in patients with inherited glycosylphosphatidylinositol deficiencies (IGDs).MethodsIn this prospective open-label multicenter pilot study, we enrolled patients diagnosed with IGDs using flow cytometry and/or genetic tests. The patients received oral pyridoxine (20–30 mg/kg/day) for 1 year, in addition to previous treatment.ResultsAll nine enrolled patients (mean age: 66.3 ± 44.3 months) exhibited marked decreases in levels of CD16, a glycosylphosphatidylinositol-anchored protein, on blood granulocytes. The underlying genetic causes of IGDs were PIGO, PIGL, and unknown gene mutations in two, two, and five patients, respectively. Six patients experienced seizures, while all patients presented with developmental delay (mean developmental age: 11.1 ± 8.1 months). Seizure frequencies were markedly (>50%) and drastically (>90%) reduced in three and one patients who experienced seizures, respectively. None of the patients presented with seizure exacerbation. Eight of nine patients exhibited modest improvements in development (P = 0.14). No adverse events were observed except for mild transient diarrhea in one patient.ConclusionOne year of daily high-dose pyridoxine treatment was effective in the treatment of seizures in more than half of our patients with IGDs and modestly improved development in the majority of them. Moreover, such treatment was reasonably safe. These findings indicate that high-dose pyridoxine treatment may be effective against seizures in patients with IGDs, although further studies are required to confirm our findings. (University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number: UMIN000024185.) 相似文献
5.
Dopamine transporter binding in
chronic manganese intoxication 总被引:2,自引:0,他引:2
Abstract.
Chronic exposure to manganese may induce parkinsonism
similar to idiopathic Parkinsons disease (PD). However,
clinical manifestations of manganism also have some features
different from PD. The mechanisms of manganese-induced
parkinsonism remain not fully understood.
99mTc-TRODAT-1 is a cocaine analogue
that can bind to the dopamine transporter (DAT) site reflecting
the function of presynaptic dopaminergic terminals. The purpose
of this study was to evaluate DAT function using
99mTc-TRODAT-1 to investigate the
integrity of the presynaptic dopaminergic terminals in
manganese-induced parkinsonism. Brain
99mTc-TRODAT-1 single photon emission
computed tomography was performed in 4 patients with chronic
manganese intoxication in a ferromanganese smelting plant in
Taiwan. Twelve PD patients and 12 healthy volunteers served as
abnormal and normal controls, respectively. Clinically, all
manganism patients had a bradykinetic-rigid syndrome. The scores
of the Unified Parkinsons Disease Rating Scale ranged between
19 and 64. The uptake values of the
99mTc-TRODAT-1 were 0.868±0.136 in
the right corpus striatum and 0.865±0.118 in the left, as
compared with 0.951±0.059 and 0.956±0.058, respectively for the
normal controls. The data were significantly higher than
0.250±0.070 and 0.317±0.066 respectively for the PD patients.
Interestingly, there was a mild decrease in the uptake of
99mTc-TRODAT-1 in the putamen and the
ratio of putamen and caudate when compared with the normal
controls. Although the DAT shows a slight decrease in the
putamen of manganism patients as compared with that of the
normal controls, the data indicate that the presynaptic
dopaminergic terminals are not the main target of chronic
manganese intoxication. In addition
99mTc-TRODAT-1 SPECT can provide a
useful, convenient and inexpensive tool for differentiation
between chronic manganism and PD. 相似文献
6.
7.
S Chokroverty R Khedekar B Derby R Sachdeo C Yook F Lepore W Nicklas R C Duvoisin 《Neurology》1984,34(11):1451-1455
We report the neuropathologic findings in the first patient with recognized glutamate dehydrogenase (GDH) deficiency to come to postmortem examination. He had progressive cerebellar ataxia beginning at age 21. He died at age 47 of pulmonary emboli. Postmortem examination revealed pancerebellar, olivary, and mild pontine atrophy, demyelination of the posterior columns, degeneration of anterior horn and dorsal root ganglion cells, and reduction of myelinated fibers in the sural nerve. In addition, there was neuronal storage of lipopigment diffusely throughout the CNS and the autonomic neurons, with cell distention, atrophy, and loss in selected areas. 相似文献
8.
Manganese (Mn)-induced neurotoxicity can occur due to environmental exposure (air pollution, soil, water) and/or metabolic aberrations (decreased biliary excretion). High brain manganese levels lead to oxidative stress, as well as alterations in neurotransmitter metabolism with concurrent neurobehavioral deficits. Based on the few existing studies that have examined brain regional Mn concentration, it is likely that in pathological conditions, Mn concentration can reach between 100 and 500 microM. Environmental Mn exposure as a result of methylcyclopentadienyl manganese tricarbonyl (MMT) combustion is in the form of phosphate or sulfate (MnPO4, MnSO4, respectively). Pharmacokinetic studies have shown that the Mn salt will determine the rate of transport into the brain: MnCl2 > MnSO4 > MnPO4. The salt-specific neurotoxicity of these species is unknown. The primary goal of this study was to examine gene expression of glutamate/aspartate transporter (GLAST), taurine transporter (tau-T), and metallothionein-I (MT-I) in astrocytes exposed to manganese chloride (MnCl2), manganese sulfate (MnSO4), and manganese phosphate (MnPO4). We hypothesized that the effects of MnPO4 and MnSO4 exposure on GLASTexpression in astrocytes would be similar to those induced by MnCl2, since irrespective of salt species exposure, once internalized by astrocytes, the Mn ion would be identically complexed. At the same time, we hypothesized that the magnitude of the effect would be salt-dependent, since the chemical speciation would determine the rate of intracellular uptake of Mn. MnCl2 caused a significant overall decrease (P < 0.0001) in astrocytic GLAST mRNA levels with MnSO4 causing a moderate decrease. MnPO4 exposure did not alter GLAST mRNA in astrocytes. We also sought to examine astrocytic metallothionein and taurine transporter gene expression as markers of manganese exposure. Our findings suggest that manganese chloride significantly decreased (P < 0.0001) astrocytic metallothionein mRNA compared to both the sulfate and phosphate species. However, astrocytic taurine transporter mRNA was not affected by Mn exposure, irrespective of the salt species. These data are consistent with the hypothesis that astrocytic neurotoxicity due to Mn exposure is dependent upon its species, with solubility, and by inference, intracellular concentration, representing a major determinant of its neurotoxicity. 相似文献
9.
10.
11.
葡萄糖转运体1缺乏综合征是一种由于SLC2A1基因突变导致的罕见神经系统代谢性疾病,临床症状复杂多样,包括早发性癫痫、发育迟滞、运动障碍等,生酮饮食能够有效改善葡萄糖转运体1缺乏综合征患者的临床症状及预后,并且越早治疗,预后越好。文中从发病机制、临床表现、辅助检查及治疗4个方面对葡萄糖转运体1缺乏综合征进行综述,以提高广大临床医生对该病的认识,提高诊断能力,改善患者预后。 相似文献
12.
正Dopamine(DA)is one of the brain’s fundamental neurotransmitters.Despite the fact that the dopaminergic synapses constitute less than 1%of all brain synapses,DA is implicated in a number of critical physiological functions and 相似文献
13.
14.
Mitochondrial disorders are varied in their clinical presentation and pathogenesis. Diagnosis is usually made clinically and genetic defects are often not identified. We present a 6-year-old female patient with a diagnosis of a mitochondrial disorder secondary to complex I deficiency with seizures and developmental delay from infancy. Glucose transporter deficiency was suspected after a lumbar puncture showed hypoglycorrhachia. Her disorder was confirmed genetically as a mutation in her solute carrier family 2, facilitated glucose transporter member 1 (SLCA2) gene. Delayed diagnosis led to delayed treatment, and neurologic sequelae may have been prevented by earlier recognition of this disorder. 相似文献
15.
Anand G Padeniya A Hanrahan D Scheffer H Zaiwalla Z Cox D Mann N Hewertson J Price S Nemeth A Arsov T Scheffer I Jayawant S Pike M McShane T 《Developmental medicine and child neurology》2011,53(7):664-668
Glucose transporter type 1 deficiency syndrome (GLUT1DS) is a treatable condition resulting from impaired glucose transport into the brain. The classical presentation is with infantile-onset epilepsy and severe developmental delay. Non-classical phenotypes with movement disorders and early-onset absence epilepsy are increasingly recognized and the clinical spectrum is expanding. The hallmark is hypoglycorrhachia (cerebrospinal fluid [CSF] glucose<2.2 mmol/l) in the presence of normoglycaemia with a CSF/blood glucose ratio of less than 0.4. GLUT1DS is due to a mutation in the solute carrier family 2, member 1 gene (SLC2A1). We present five individuals (four males, one female), all of whom had a mild phenotype, highlighting the importance of considering this diagnosis in unexplained neurological disorders associated with mild learning difficulties, subtle motor delay, early-onset absence epilepsy, fluctuating gait disorders, and/or dystonia. The mean age at diagnosis was 8 years 8 months. This paper also shows phenotypical parallels between GLUT1DS and paroxysmal exertion-induced dyskinesia. 相似文献
16.
Two unrelated children with thrombotic disease associated with inherited protein S deficiency and osteopenia have been identified. Measurement of protein S yielded markedly reduced levels of free protein S (less than 12.5%) in both propositi, a normal level of total protein S (79%) in propositus #1, and markedly reduced level of total protein S (34%) in propositus #2. Bone densitometry measurements of the two children revealed trabecular vertebral bone mineral content below two standard deviations. This defect is associated with vertebral body compression fractures in propositus #2. Therefore, it is hypothesized that protein S deficiency is associated with abnormalities of bone mineral density. 相似文献
17.
Impaired glucose transport across the blood brain barrier results in glucose transporter type 1 (GLUT-1) deficiency syndrome, first described in 1991. It is characterized by infantile seizures refractory to anticonvulsive treatments, microcephaly, delays in mental and motor development, spasticity, ataxia, dysarthria and other paroxysmal neurologic phenomena, often occurring prior to meals. Affected infants are normal at birth following an uneventful pregnancy and delivery. Seizures usually begin between the age of one and four months and can be preceded by apneic episodes or abnormal eyes movements. Patients with atypical presentations such as mental retardation and intermittent ataxia without seizures, or movement disorders characterized by choreoathetosis and dystonia, have also been described. Glucose is the principal fuel source for the brain and GLUT-1 is the only vehicle by which glucose enters the brain. In case of GLUT-1 deficiency, the risk of clinical manifestations is increased in infancy and childhood, when the brain glucose demand is maximal. The hallmark of the disease is a low glucose concentration in the cerebrospinal fluid in a presence of normoglycemia (cerebrospinal fluid/blood glucose ratio less than 0.4). The GLUT-1 defect can be confirmed by molecular analysis of the SCL2A1 gene or in erythrocytes by glucose uptake studies and GLUT-1 immunoreactivity. Several heterozygous mutations, with a majority of de novo mutations, resulting in GLUT-1 haploinsufficiency, have been described. Cases with an autosomal dominant transmission have been established and adults can exhibit symptoms of this deficiency. Ketogenic diet is an effective treatment of epileptic manifestations as ketone bodies serve as an alternative fuel for the developing brain. However, this diet is not effective on cognitive impairment and other treatments are being evaluated. The physiopathology of this disorder is partially unclear and its understanding could explain the clinical heterogeneity of GLUT-1 deficiency patients and lead to new treatments. This probably under-diagnosed deficiency should be suspected in children with unexplained neurological disorders including epilepsy, mental retardation and movement disorders and confirmed by a lumbar puncture and the direct sequencing of GLUT-1. 相似文献
18.
Todor Arsov PhD Saul A. Mullen MBBS PhD Sue Rogers PhD A. Marie Phillips PhD Kate M. Lawrence BSc John A. Damiano BSc Hadassa Goldberg‐Stern MD Zaid Afawi MD Sara Kivity MD Chantal Trager BSc Steven Petrou PhD Samuel F. Berkovic FRS Ingrid E. Scheffer MBBS PhD 《Annals of neurology》2012,72(5):807-815
19.
Glucose transporter 1 deficiency syndrome is emblematic of a brain energy failure syndrome. Energy failure also results from other genetically determined metabolic disorders, such as hypoglycemic syndromes, hypoketonemic syndromes associated with fatty acid oxidation defects, glycolytic enzymopathies, and mitochondrial defects. Glucose transporter 1 deficiency syndrome is particularly illustrative of this group of disorders and produces an infantile-onset epileptic encephalopathy that responds to a ketogenic diet. The electroencephalographic correlate is distinctive and emerges as a 2.5- to 4-Hz spike-wave discharge in late infancy to early childhood. Infantile apnea and oscillatory eye movements reminiscent of opsoclonus may be the earliest signs of this condition. Mutations of the GLUT1 gene are causative and transmitted as an autosomal dominant trait. Thioctic acid is a glucose transporter 1 activator, whereas barbiturates and methylxanthines are glucose transporter 1 inhibitors. The ketogenic diet is effective treatment for glucose transporter 1 deficiency syndrome and pyruvate dehydrogenase deficiency. It also should benefit patients with neurologic symptoms resulting from a glycolytic enzymopathy. 相似文献
20.
Glucose transporter type1 (GLUT-1) deficiency 总被引:3,自引:0,他引:3
Glucose transporter type1 (GLUT-1) deficiency may be rare, but it is a preventable cause of severe learning difficulties; and therefore there is an urgency in making an early diagnosis. Suspicions must be roused when intractable seizures occur in infancy. These may be associated with acquired microcephaly and developmental delay. The finding of low glucose sugar levels in the cerebrospinal fluid, but not in the blood will identify the condition. The gene encoding the GLUT-1 protein is located on the short arm of chromosome 1, and inheritance is by a dominant trait. Patients with this syndrome can have heterozygous mutations, with one allele being a normal wild type and one being mutant. An efficient transport of glucose across the blood-brain barrier is essential as it is such an important fuel for the brain, and this is provided by glucose transporter type1 in the endothelial cells of the brain capillaries. Another minor contribution to the symptomatology of GLUT-1 may be impaired transport of an oxidised form of vitamin C. Treatment with anti-epileptic drugs may be needed, and the ketogenic diet may reduce symptoms, as ketosis can provide an alternative source of fuel for the brain. It has also been suggested that antioxidant thioctic acid may be of benefit. Substances such as caffeine and phenobarbitone should be avoided as they inhibit glucose transport. 相似文献